+

Cookies on the Business Insider India website

Business Insider India has updated its Privacy and Cookie policy. We use cookies to ensure that we give you the better experience on our website. If you continue without changing your settings, we\'ll assume that you are happy to receive all cookies on the Business Insider India website. However, you can change your cookie setting at any time by clicking on our Cookie Policy at any time. You can also see our Privacy Policy.

Close
HomeQuizzoneWhatsappShare Flash Reads
 

Study results for a leading potential coronavirus treatment were accidentally released by the WHO and then taken down

Apr 23, 2020, 23:19 IST
Business Insider
FILE - In this March 2020 photo provided by Gilead Sciences, a vial of the investigational drug remdesivir is visually inspected at a Gilead manufacturing site in the United States. Given through an IV, the medication is designed to interfere with an enzyme that reproduces viral genetic material. (Gilead Sciences via AP)Associated Press
  • The World Health Organization accidentally posted study results showing that a leading potential coronavirus treatment did not help a group of patients with severe coronavirus cases, according to a new report from STAT.
  • STAT reported Thursday that "a summary of the study results was inadvertently posted" to the WHO's website.
  • Those results failed to show patients improving faster when given remdesivir. After a month in this study from China, 13.9% of patients on the antiviral drug died compared to 12.8% on the placebo arm, according to STAT.
  • Gilead Sciences, which developed remdesivir and is now testing it in its own trials, did not immediately respond to a request for comment from Business Insider.
  • Visit Business Insider's homepage for more stories.
Advertisement

A leading coronavirus treatment candidate did not help severe coronavirus patients survive better than a placebo group, according to study results reported by STAT.

STAT reported that the World Health Organization's website accidentally posted a summary of study results showing the experimental antiviral drug remdesivir did not benefit patients.

The WHO has since taken down the inadvertent posting. Gilead and WHO did not immediately respond to requests for comment. Gilead's stock fell 5.9% to $76.51 on Thursday afternoon.

According to STAT, the posting showed that 13.9% of patients on remdesivir died after a month of follow-up, compared to 12.8% who got a placebo. The trial was focused on a group of patients with severe COVID-19.

It is the second unusual leak of remdesivir data in a matter of days. STAT had also reported on a leaked video showing University of Chicago researchers discussing promising results from a different remdesivir study.

Advertisement

This is a breaking news story and will be updated.

Read the original article on Business Insider
You are subscribed to notifications!
Looks like you've blocked notifications!
Next Article